GENTIAN DIAGNOST. NO -01
Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe. The company offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Circulating Calprotectin Immunoassay, a turbidimetric assay used for the measurement of calprotectin in plasma and serum for detection and… Read more
GENTIAN DIAGNOST. NO -01 (6FK) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, GENTIAN DIAGNOST. NO -01 (6FK) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
GENTIAN DIAGNOST. NO -01 - Net Assets Trend (None–None)
This chart illustrates how GENTIAN DIAGNOST. NO -01's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for GENTIAN DIAGNOST. NO -01 (None–None)
The table below shows the annual net assets of GENTIAN DIAGNOST. NO -01 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to GENTIAN DIAGNOST. NO -01's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
GENTIAN DIAGNOST. NO -01 Competitors by Market Cap
The table below lists competitors of GENTIAN DIAGNOST. NO -01 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Lorne Park Capital Partners Inc
V:LPC
|
$42.59 Million |
|
Sungmoon Electronics Co Ltd
KO:014915
|
$42.61 Million |
|
Suyog Telematics Limited
NSE:SUYOG
|
$42.61 Million |
|
Kross Ltd
NSE:KROSS
|
$42.63 Million |
|
NameSilo Technologies Corp
PINK:URLOF
|
$42.58 Million |
|
NEOMETALS LTD SP.ADS/10
F:9R91
|
$42.56 Million |
|
KT Hitel Corporation. Limited
KQ:036030
|
$42.56 Million |
|
Max India Limited
NSE:MAXIND
|
$42.54 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in GENTIAN DIAGNOST. NO -01's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares GENTIAN DIAGNOST. NO -01's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently GENTIAN DIAGNOST. NO -01 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares GENTIAN DIAGNOST. NO -01's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $253,026,393
- Average return on equity (ROE) among peers: -74.55%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| GENTIAN DIAGNOST. NO -01 (6FK) | €- | N/A | N/A | $42.58 Million |
| HeraMED Limited (1I4) | $-105.98K | 0.00% | 0.00x | $18.56 Million |
| Q-linea AB (publ) (3F80) | $163.19 Million | -164.65% | 0.41x | $9.44 Million |
| Guerbet SA (4G8) | $342.14 Million | 13.51% | 1.79x | $44.18 Million |
| Scandinavian Real Heart AB (Publ) (7820) | $111.29 Million | -9.42% | 0.06x | $4.94 Million |
| aap Implantate AG (AAQ1) | $54.78 Million | 26.71% | 0.17x | $9.65 Million |
| Carmat SA (CXT) | $7.48 Million | -557.76% | 3.92x | $1.62 Million |
| elexxion AG (E8X) | $-0.01 | 0.00% | 0.00x | $199.10K |
| AETHLON MEDIC.NEW DL-001 (EJU) | $15.06 Million | -79.86% | 0.16x | $446.12K |
| Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ) | $139.44 Million | 15.79% | 0.97x | $615.93 Million |
| Gaush Meditech Ltd (F7Y) | $1.70 Billion | 10.23% | 0.68x | $29.29 Million |